HDAC9‐mediated calmodulin deacetylation induces memory impairment in Alzheimer's disease
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14573 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Hai-Long Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Neuropsychiatric Diseases, Institute of Neuroscience, Suzhou Medical College of Soochow University, Medical Center of Sooch…. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Themen: Demenz
Abstract (Originalsprache)
Aims
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive dysfunction and memory impairment. AD pathology involves protein acetylation. Previous studies have mainly focused on histone acetylation in AD, however, the roles of nonhistone acetylation in AD are less explored.
Methods
The protein acetylation and expression levels were detected by western blotting and co‐immunoprecipitation. The stoichiometry of acetylation was measured by home‐made and site‐specific antibodies against acetylated‐CaM (Ac‐CaM) at K22, K95, and K116. Hippocampus‐dependent learning and memory were evaluated by using the Morris water maze, novel object recognition, and contextual fear conditioning tests.
Results
We showed that calmodulin (CaM) acetylation is reduced in plasma of AD patients and mice. CaM acetylation and its target Ca 2+ /CaM‐dependent kinase II α (CaMKIIα) activity were severely impaired in AD mouse brain. The stoichiometry showed that Ac‐K22, K95‐CaM acetylation were decreased in AD patients and mice. Moreover, we screened and identified that lysine deacetylase 9 (HDAC9) was the main deacetylase for CaM. In addition, HDAC9 inhibition increased CaM acetylation and CaMKIIα activity, and hippocampus‐dependent memory in AD mice.
Conclusions
HDAC9‐mediated CaM deacetylation induces memory impairment in AD, HDAC9, or CaM acetylation may become potential therapeutic targets for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, Institute of Neuroscience, Suzhou Medical College of Soochow University, Medical Center of Soochow University, Suzhou, China.
- Key Laboratory of Brain Functional Genomics, Ministry of Education and Shanghai, School of Life Science, East China Normal University, Shanghai, China.
- Department of Neurology, The Affiliated Xingyi City Hospital of Guizhou Medical University, Xingyi, China.
ORCID-Profile: Hai-Long Zhang, Guang-Yin Xu
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Zhang, H. L., Hu, S., Yang, P., Long, H. C., Ma, Q. H., Yin, D. M., & Xu, G. Y. (2024). HDAC9‐mediated calmodulin deacetylation induces memory impairment in Alzheimer's disease. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14573
Vancouver
Zhang HL, Hu S, Yang P, Long HC, Ma QH, Yin DM, et al. HDAC9‐mediated calmodulin deacetylation induces memory impairment in Alzheimer's disease. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14573
BibTeX
@article{Zhang2024,
author = {Zhang, Hai-Long and Hu, Shufen and Yang, Pin and Long, Han-Chun and Ma, Quan-Hong and Yin, Dong-Min and Xu, Guang-Yin},
title = {HDAC9‐mediated calmodulin deacetylation induces memory impairment in Alzheimer's disease},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14573}
}
EUVIMED